Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Kyle LaHucik

Senior Reporter

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals’ pain drug approval last month, is targeting up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

UnitedHealth reports 'unusual and unacceptable' earnings as Medicare costs climb

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

CMS would absorb 340B drug discount program under leaked HHS reorganization proposal

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Pain biotech Lati­go eyes up to $150M raise fol­low­ing Ver­tex's land­mark FDA nod

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Unit­ed­Health re­ports 'unusu­al and un­ac­cept­able' earn­ings as Medicare costs climb

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

CMS would ab­sorb 340B drug dis­count pro­gram un­der leaked HHS re­or­ga­ni­za­tion pro­pos­al

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

UnitedHealth reports 'unusual and unacceptable' earnings as Medicare costs climb

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

CMS would absorb 340B drug discount program under leaked HHS reorganization proposal

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence